AlgiPharma was recently granted patent protection in its ongoing National Phase of PCT Application PCT/EP2017/076926 for “Bacitracin-alginate oligomer conjugates”. This adds to AlgiPharma’s growing patent portfolio. About AlgiPharma AS: AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the […]
AlgiPharma was recently granted patent protection for its European Patent No. 3528830 (17791037.9) Polymyxin-alginate oligomer conjugates. This adds to AlgiPharma’s growing patent portfolio. About AlgiPharma AS: AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology […]
AlgiPharma’s collaboration partners in Cardiff University have recently published an article on the potentiating effects of AlgiPharma’s alginate oligosaccharide technology: Stokniene J, Varache M, Rye PD, Hill KE, Thomas DW, Ferguson EL. Alginate oligosaccharides enhance diffusion and activity of colistin in a mucin-rich environment. Sci Rep. 2022 Mar 23;12(1):4986. doi: 10.1038/s41598-022-08927-1. PMID: 35322119; PMCID: […]
AlgiPharma in collaboration with its clinical trials team for the randomized clinical trial NCT02453789 in CF has recently been published: Fischer R, Schwarz C, Weiser R, Mahenthiralingam E, Smerud K, Meland N, Flaten H, Rye PD. Evaluating the alginate oligosaccharide (OligoG) as a therapy for Burkholderia cepacia complex cystic fibrosis lung infection. J Cyst Fibros. […]
January 27th 2022 AlgiPharma was featured in DelveInsights’s “Cystic Fibrosis Pipeline Insight, 2022” report that provides insight on company and pipeline activities in the Cystic Fibrosis therapeutics landscape. The report highlights around 60+ products under development by companies working on novel opportunities that could influence Cystic Fibrosis treatment. The report provides insights into different therapeutic […]
AlgiPharma has been awarded up to NOK 16 million from the Norwegian Research Councils Innovation Project for the Industrial Sector program for the project “Therapeutic Alginates for Resistant and Recurrent Infections: Generating Eradication Therapies (TARRGET)”. The project grant awarded from the Research Council combined with the Norwegian government tax incentive scheme (SkatteFUNN) results in a […]
AlgiPharma has been awarded up to NOK 16 million from the Norwegian Research Council.
Director Clinical Research / Chief Medical Officer AlgiPharma is interested to hear from high caliber, energetic candidates to join the team at our Norwegian office in Sandvika. The deadline for applications is the 24th May 2020 (see links below for further details). More details can be found at: – www.borka.no/jobb/director-clinical-research-chief-medical-officer/ – www.finn.no/177948590 – www.linkedin.com/groups/2085624 – […]
AlgiPharma AS acquired by AlgiPharma AB On December 20, 2019 the Swedish AlgiPharma AB finalized the acquisition of the Norwegian AlgiPharma AS. All shareholders in AlgiPharma AS accepted the offer from AlgiPharma AB which means that the shareholders have the same number of shares and ownership percentage in the new parent company AlgiPharma AB as […]
AlgiPharma appoints Fredrik Alpsten as new Chief Financial Officer (CFO) Mr Alpsten has an MSc degree from Stockholm School of Economics. He has 25 years of operational, financial, and strategic business experience as an executive in the life science field. He has served as Senior Vice President and CFO of Boule Diagnostics AB, a Swedish […]
